Am J Transplant, Volume 19, Suppl 3 Archives - Page 200 of 214 - ATC Abstracts

2019 American Transplant Congress
Post-Transplant Lymphoproliferative Disorders after Living-Donor Liver Transplantation: A Retrospective Cohort Study in 1,900 Cases of Single Center Experience
T. Tajima¹, K. Hata¹, H. Haga², M. Nishikori³, J. Kusakabe¹, I. Tamaki¹, T. Ito¹, T. Kaido¹, A. Takaori-Kondo³, S. Uemoto¹
¹Div. of HBP Surgery and Transplantation, Dept. of Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, ²Dept. of Diagnostic Pathology, Kyoto University Hospital, Kyoto, Japan, ³Dept. of Hematology and Oncology, Kyoto University Graduate School of Medicine, Kyoto, Japan
*Purpose: Post-transplant lymphoproliferative disorders (PTLD) is relatively rare but the most common, life-threatening neoplasms after organ transplantation. Because of their heterogeneity from benign to malignant…
2019 American Transplant Congress
Identification of Adult Liver Transplant Recipients Eligible to Participate in an Immunosuppression Withdrawal Trial Employing Non-Invasive Assessments of Allograft Status
J. Vionnet¹, R. Miquel¹, A. Douiri¹, M. Elstad¹, E. Kodela¹, A. Quaglia², J. Wall¹, P. Ruiz Martin¹, E. B. Riani³, J. Leithead⁴, A. Marshall², M. Navasa⁵, P. Ruiz⁵, J. Ferguson⁶, K. Simpson⁷, A. Pascher⁸, E. Jaeckel⁹, R. Bishop¹⁰, F. Nevens¹¹, S. Masson¹², A. Sanchez-Fueyo¹
¹King's College London, London, United Kingdom, ²Royal Free, London, United Kingdom, ³St-Luc, Brussels, Belgium, ⁴Addenbrookes, Cambridge, United Kingdom, ⁵Hospital Clinic, Barcelona, Spain, ⁶Queen Elizabeth, Birmingham, United Kingdom, ⁷Royal Infirmary, Edinburgh, United Kingdom, ⁸Charité, Berlin, Germany, ⁹Hannover Medical School, Hannover, Germany, ¹⁰Leeds NHS Trust, Leeds, United Kingdom, ¹¹UZ Leuven, Leuven, Belgium, ¹²Hepatology, Newcastle, United Kingdom
*Purpose: Liver Immunosuppression Free Trial (LIFT) is a multicentre international prospective randomised controlled trial of biomarker-guided immunosuppression withdrawal in adult liver transplant recipients who meet…
2019 American Transplant Congress
Clinical Trial of Allogeneic Islet Transplantation in the Treatment of Diabetes after Renal Transplantation
W. liang, M. Hu, G. Peng, D. Zhou, C. Zeng, W. Zhou, q. Ye, Z. Wang
Zhongnan Hospital of Wuhan University, Institute of Hepatobiliary Diseases, Wuhan, China
*Purpose: Diabetes after renal transplantation is one of the most serious complications after renal transplantation. It has a serious impact to the survival of kidney…
2019 American Transplant Congress
Ex Vivo Assessment of Marginal Human Kidneys Using Computed Tomography
M. K. Harris¹, J. R. DiRito², H. Liu³, N. Boutagy³, C. Liu⁴, S. Hosgood², D. Mulligan¹, M. L. Nicholson², A. Sinusas³, D. Haakinson¹, G. T. Tietjen¹
¹Surgery, Yale School of Medicine, New Haven, CT, ²Surgery, University of Cambridge, Cambridge, United Kingdom, ³Yale Translational Research Imaging Center, New Haven, CT, ⁴Radiology, Yale School of Medicine, New Haven, CT
*Purpose: Thousands of ‘marginal’ organs are discarded each year despite a severe organ shortage. This has motivated development of new technologies, such as ex vivo…
2019 American Transplant Congress
Combined Thoracic-Liver Transplants Using Normothermic Machine Perfusion for Liver Preservation: A Case Series
M. Rizzari, K. Crombez, S. Nagai, J. Stracke, A. Al-Kurd, K. Collins, A. Yoshida, M. Abouljoud
Henry Ford Transplant Institute, Detroit, MI
*Purpose: There is minimal data describing combined thoracic-liver transplants (tx) with normothermic machine perfusion (NMP) used for liver preservation as the thoracic tx is done.…
2019 American Transplant Congress
Pluripotent Stem Cell Differentiation: Delaying Forward Differentiation Signals Maintains Definitive Endoderm Phenotype for Cellular Transplantation
J. Fair¹, M. M. Shoja¹, N. Liu¹, I. Patrikeev², M. Motamedi², W. S. Fagg¹
¹Surgery, University of Texas Medical Branch, Galveston, TX, ²Opthalmology and Visual Sciences, University of Texas Medical Branch, Galveston, TX
*Purpose: Endodermal precursors (EP), derived in vitro from mouse pluripotent stem cell (PSC) sources, are capable of clinically useful engraftment in the unmodified (quiescent) liver…
2019 American Transplant Congress
Endogenous Erythropoietin is Required for Spontaneous Acceptance of Murine Renal Allografts
J. Horwitz, P. Cravedi, P. Heeger
Icahn School of Medicine at Mount Sinai, NY, NY
*Purpose: B6 recipients spontaneously accept MHC-disparate renal allografts from allogeneic DBA/2 x B6 (H-2d x H-2b) F1 donors via mechanisms that are in part regulatory…
2019 American Transplant Congress
Novel Insights into Blocking the IL-6 / IL-6 Receptor Pathway after Pig Kidney Xenotransplantation in Baboons
H. Hara¹, G. Zhang¹, H. Iwase¹, T. Yamamoto¹, D. Ayares², D. E. Eckhoff¹, D. K. Cooper¹
¹Surgery, University of Alabama at Birmingham, Birmingham, AL, ²Revivicor Inc., Blacksburg, VA
*Purpose: IL-6 plays an important role in inflammation. The aims of the study were (i) to measure IL-6 in serum in baboons that received IL-6…
2019 American Transplant Congress
Role of Innate Allorecognition Pathways in Mouse Renal Allograft Rejection
D. Zhao¹, H. Dai¹, K. Abou-Daya¹, A. Williams¹, M. Oberbarnscheidt¹, X. Li², F. Lakkis¹
¹Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh, PA, ²Houston Methodist Hospital Immunobiology & Transplant Science Center, Houston, TX
*Purpose: Allograft rejection is initiated by host immune system distinguishing between self and allogeneic non-self (allorecognition). Paired immunoglobulin-like receptor (PIR) and CD47 are molecules expressed…
2019 American Transplant Congress
Longer-Term Outcomes for Hepatitis C Virus Negative Recipients of Kidneys from Hepatitis C Virus Nucleic Acid Test Positive Donors: The THINKER Trial
P. Reese¹, P. Abt¹, E. Blumberg¹, R. Bloom¹, D. Sawinski¹, P. Porrett¹, A. Woodards¹, K. Reddy¹, V. van Deerlin¹, R. Hasz², M. Levine¹, R. McLean¹, A. Sicilia¹, D. Goldberg¹
¹University of Penn, Philadelphia, PA, ²Gift of Life, Philadelphia, PA
*Purpose: Two trials of transplanting hepatitis C virus (HCV) nucleic acid test (NAT) positive kidneys into HCV-negative recipients have been published, both with 100% HCV…